Physician profile
Thomas D Ward
NPI 1992770812
$438.56
in general payments reported to CMS, 2019-2025
7 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $23.35 · 2021: $272.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $161.55 | 2021 | |
| Novo Nordisk INC | $90.44 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $85.92 | 2019 | |
| Astrazeneca Pharmaceuticals Lp | $32.82 | 2019 | |
| Mallinckrodt Enterprises LLC | $24.79 | 2019 | |
| Daiichi Sankyo INC. | $23.35 | 2020 | |
| Aurinia Pharma U.S., INC. | $19.69 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Ward listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.